Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BTTX |
---|---|---|
09:32 ET | 42836 | 0.013 |
09:34 ET | 7230 | 0.013 |
09:41 ET | 1000 | 0.01455 |
09:48 ET | 1000 | 0.016 |
09:50 ET | 9000 | 0.01455 |
09:57 ET | 4000 | 0.01455 |
10:01 ET | 5921 | 0.0131 |
10:06 ET | 9775 | 0.01484 |
10:14 ET | 3618 | 0.0131 |
10:24 ET | 75000 | 0.01455 |
10:26 ET | 50000 | 0.013 |
10:30 ET | 10000 | 0.0148 |
10:33 ET | 7973 | 0.0135 |
10:35 ET | 5000 | 0.0145 |
10:39 ET | 10000 | 0.0142 |
10:42 ET | 4200 | 0.0145 |
10:48 ET | 5000 | 0.01375 |
10:53 ET | 27899 | 0.013 |
10:57 ET | 300 | 0.0145 |
11:04 ET | 82700 | 0.0137 |
11:06 ET | 20010 | 0.0129 |
11:08 ET | 15000 | 0.01386 |
11:09 ET | 12500 | 0.01386 |
11:18 ET | 1970 | 0.01306 |
11:24 ET | 200 | 0.0129 |
11:33 ET | 100 | 0.0145 |
11:40 ET | 126649 | 0.0129 |
11:58 ET | 10000 | 0.01354 |
12:20 ET | 79277 | 0.0127 |
12:50 ET | 6345 | 0.01435 |
01:10 ET | 1000 | 0.01414 |
01:46 ET | 15000 | 0.016 |
01:48 ET | 9438 | 0.0134 |
01:53 ET | 15000 | 0.01522 |
02:13 ET | 4000 | 0.01496 |
02:18 ET | 30520 | 0.015 |
02:26 ET | 10000 | 0.0135 |
02:27 ET | 100 | 0.0134 |
02:40 ET | 100000 | 0.015 |
02:45 ET | 43255 | 0.0148 |
02:47 ET | 15000 | 0.016 |
02:49 ET | 500 | 0.0148 |
02:54 ET | 2768 | 0.0148 |
03:20 ET | 1000 | 0.0148 |
03:25 ET | 16532 | 0.0134 |
03:56 ET | 237 | 0.014 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Better Therapeutics Inc | 643.2K | 0.0x | --- |
Ampio Pharmaceuticals Inc | 682.3K | -0.1x | --- |
GRI Bio Inc | 584.2K | 0.0x | --- |
Bellerophon Therapeutics Inc | 695.0K | -0.1x | --- |
Evelo Biosciences Inc | 823.5K | 0.0x | --- |
Capstone Holding Corp | 819.6K | -0.8x | --- |
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $643.2K |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.16 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.